Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04379999 · ClinicalTrials.gov registry record · Early Phase 1
Atorvastatin ± Aspirin in Lynch Syndrome Syndrome
A Early Phase 1 study, sponsored by Fox Chase Cancer Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 43
- Enrollment target
NCT04379999 is a Early Phase 1 study that has completed, run by Fox Chase Cancer Center. The registered enrollment target is 43 participants.
The verdict
NCT04379999, a Early Phase 1 study, has completed, sponsored by Fox Chase Cancer Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 43 participants
- Enrollment target
Study Summary
The goal of this study is to investigate that a common cholesterol lowering agent (atorvastatin) alone or combining with a nonsteroidal anti-inflammatory drug (aspirin) would reduce the risk of colorectal cancer (CRC) in high-risk individuals with Lynch syndrome.
Interventions
- DRUG Atorvastatin 20mg
- DRUG Atorvastatin 20mg AND Aspirin 325 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2018-09-10 |
| Est. Completion | 2025-08-04 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04379999
The ClinicalTrials.gov registry entry for NCT04379999 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Atorvastatin 20mg is the first listed.
NCT04379999 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04379999 about?
NCT04379999 is a clinical study titled "Atorvastatin ± Aspirin in Lynch Syndrome Syndrome". The goal of this study is to investigate that a common cholesterol lowering agent (atorvastatin) alone or combining with a nonsteroidal anti-inflammatory drug (aspirin) would reduce the risk of colorectal cancer (CRC) in high-risk individuals with Lynch syndrome.
What is the current status of trial NCT04379999?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 43 participants. The study started on 2018-09-10. Estimated completion is 2025-08-04.
What interventions are being tested in trial NCT04379999?
The interventions under investigation include: Atorvastatin 20mg (DRUG), Atorvastatin 20mg AND Aspirin 325 mg (DRUG).
Who is sponsoring clinical trial NCT04379999?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.